Congress funds $75M brain tumor research push, expands patient trial access
S. 1330 — BRAIN Act · Filed by Richard Blumenthal (D-CT) · 9 cosponsors · Introduced Apr 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes $75 million over five years (2026–2030) for NIH-led research and public awareness programs focused on brain tumors and cancer treatment. It creates a searchable registry of biospecimen collections, funds a Glioblastoma Therapeutics Network ($50M) and CAR-T immunotherapy research ($10M), launches a national public awareness campaign on clinical trials and biomarker testing ($10M), funds pilot programs for brain tumor survivor care ($5M), and directs the FDA to issue guidance expanding brain tumor patient access to clinical trials. The bill benefits patients, researchers, and the public health system by improving treatment options, awareness, and long-term survivor care.
Why we flagged it
The bill is a straightforward appropriations and research authorization for NIH-led brain tumor research, clinical trial awareness, and survivor care. It contains no deregulation, liability shields, or private carve-outs—only public funding and public health infrastructure.
What the text implies
- The biospecimen registry may increase data-sharing efficiency but could raise privacy concerns if collection metadata is insufficiently de-identified or if researchers gain access without robust consent frameworks.
- The CAR-T and glioblastoma research programs may accelerate development of expensive immunotherapies; public funding here may subsidize later commercial deployment by pharma companies, though the bill does not explicitly grant IP rights to private parties.
The full analysis lists 4 implications of this text.
Who stands to gain
Academic medical centers and cancer research institutions (grant recipients); Pharmaceutical and biotechnology companies developing CAR-T and glioblastoma therapeutics (downstrea; Health systems and community-based medical facilities (pilot program funding)